Danaher Corporation
Danaher Corporation DHR-PB Peers
See (DHR-PB) competitors and their performances in Stock Market.
Stock Comparison
DHR-PB vs TMO Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, TMO has a market cap of 152.15B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while TMO trades at $403.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas TMO's P/E ratio is 23.64. In terms of profitability, DHR-PB's ROE is +0.07%, compared to TMO's ROE of +0.13%. Regarding short-term risk, DHR-PB is less volatile compared to TMO. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs DHR Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, DHR has a market cap of 135.68B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while DHR trades at $189.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas DHR's P/E ratio is 36.74. In terms of profitability, DHR-PB's ROE is +0.07%, compared to DHR's ROE of +0.07%. Regarding short-term risk, DHR-PB is less volatile compared to DHR. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs LZAGY Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, LZAGY has a market cap of 50.75B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while LZAGY trades at $70.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas LZAGY's P/E ratio is 65.14. In terms of profitability, DHR-PB's ROE is +0.07%, compared to LZAGY's ROE of +0.06%. Regarding short-term risk, DHR-PB is less volatile compared to LZAGY. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs LZAGF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, LZAGF has a market cap of 49.22B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while LZAGF trades at $699.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas LZAGF's P/E ratio is 64.57. In terms of profitability, DHR-PB's ROE is +0.07%, compared to LZAGF's ROE of +0.06%. Regarding short-term risk, DHR-PB is less volatile compared to LZAGF. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs IDXX Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, IDXX has a market cap of 39.54B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while IDXX trades at $491.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas IDXX's P/E ratio is 45.53. In terms of profitability, DHR-PB's ROE is +0.07%, compared to IDXX's ROE of +0.57%. Regarding short-term risk, DHR-PB is less volatile compared to IDXX. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs A Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, A has a market cap of 30.49B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while A trades at $106.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas A's P/E ratio is 24.48. In terms of profitability, DHR-PB's ROE is +0.07%, compared to A's ROE of +0.21%. Regarding short-term risk, DHR-PB is less volatile compared to A. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs IQV Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, IQV has a market cap of 25.76B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while IQV trades at $148.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas IQV's P/E ratio is 20.32. In terms of profitability, DHR-PB's ROE is +0.07%, compared to IQV's ROE of +0.21%. Regarding short-term risk, DHR-PB is less volatile compared to IQV. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs WUXAY Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, WUXAY has a market cap of 23.44B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while WUXAY trades at $7.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas WUXAY's P/E ratio is 14.39. In terms of profitability, DHR-PB's ROE is +0.07%, compared to WUXAY's ROE of +0.19%. Regarding short-term risk, DHR-PB is less volatile compared to WUXAY. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs MTD Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, MTD has a market cap of 22.46B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while MTD trades at $1,080.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas MTD's P/E ratio is 27.00. In terms of profitability, DHR-PB's ROE is +0.07%, compared to MTD's ROE of +1.21%. Regarding short-term risk, DHR-PB is less volatile compared to MTD. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs WUXIF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, WUXIF has a market cap of 21.32B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while WUXIF trades at $7.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas WUXIF's P/E ratio is 13.85. In terms of profitability, DHR-PB's ROE is +0.07%, compared to WUXIF's ROE of +0.19%. Regarding short-term risk, DHR-PB is more volatile compared to WUXIF. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs NTRA Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, NTRA has a market cap of 20.60B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while NTRA trades at $151.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas NTRA's P/E ratio is -98.67. In terms of profitability, DHR-PB's ROE is +0.07%, compared to NTRA's ROE of -0.21%. Regarding short-term risk, DHR-PB is less volatile compared to NTRA. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs WAT Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, WAT has a market cap of 20.47B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while WAT trades at $343.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas WAT's P/E ratio is 31.21. In terms of profitability, DHR-PB's ROE is +0.07%, compared to WAT's ROE of +0.39%. Regarding short-term risk, DHR-PB is less volatile compared to WAT. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs DGX Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, DGX has a market cap of 19.75B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while DGX trades at $176.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas DGX's P/E ratio is 22.37. In terms of profitability, DHR-PB's ROE is +0.07%, compared to DGX's ROE of +0.13%. Regarding short-term risk, DHR-PB is less volatile compared to DGX. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs BMXMF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, BMXMF has a market cap of 15.21B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while BMXMF trades at $128.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas BMXMF's P/E ratio is 31.37. In terms of profitability, DHR-PB's ROE is +0.07%, compared to BMXMF's ROE of +0.10%. Regarding short-term risk, DHR-PB is less volatile compared to BMXMF. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs PKI Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, PKI has a market cap of 14.46B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas PKI's P/E ratio is 41.45. In terms of profitability, DHR-PB's ROE is +0.07%, compared to PKI's ROE of +0.08%. Regarding short-term risk, DHR-PB is less volatile compared to PKI. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs ILMN Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, ILMN has a market cap of 12.00B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while ILMN trades at $75.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas ILMN's P/E ratio is -9.86. In terms of profitability, DHR-PB's ROE is +0.07%, compared to ILMN's ROE of -0.42%. Regarding short-term risk, DHR-PB is less volatile compared to ILMN. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs ERFSF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, ERFSF has a market cap of 11.43B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while ERFSF trades at $64.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas ERFSF's P/E ratio is 27.53. In terms of profitability, DHR-PB's ROE is +0.07%, compared to ERFSF's ROE of +0.07%. Regarding short-term risk, DHR-PB is less volatile compared to ERFSF. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs ICLR Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, ICLR has a market cap of 10.82B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while ICLR trades at $133.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas ICLR's P/E ratio is 14.59. In terms of profitability, DHR-PB's ROE is +0.07%, compared to ICLR's ROE of +0.08%. Regarding short-term risk, DHR-PB is less volatile compared to ICLR. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs RVTY Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, RVTY has a market cap of 10.76B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while RVTY trades at $91.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas RVTY's P/E ratio is 37.70. In terms of profitability, DHR-PB's ROE is +0.07%, compared to RVTY's ROE of +0.04%. Regarding short-term risk, DHR-PB is less volatile compared to RVTY. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs TEM Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, TEM has a market cap of 10.31B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while TEM trades at $61.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas TEM's P/E ratio is -11.89. In terms of profitability, DHR-PB's ROE is +0.07%, compared to TEM's ROE of +21.50%. Regarding short-term risk, DHR-PB is less volatile compared to TEM. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs EXAS Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, EXAS has a market cap of 9.74B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while EXAS trades at $51.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas EXAS's P/E ratio is -9.34. In terms of profitability, DHR-PB's ROE is +0.07%, compared to EXAS's ROE of -0.36%. Regarding short-term risk, DHR-PB is less volatile compared to EXAS. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs QGEN Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, QGEN has a market cap of 9.05B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while QGEN trades at $41.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas QGEN's P/E ratio is 110.14. In terms of profitability, DHR-PB's ROE is +0.07%, compared to QGEN's ROE of +0.02%. Regarding short-term risk, DHR-PB is less volatile compared to QGEN. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs MEDP Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, MEDP has a market cap of 8.51B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while MEDP trades at $296.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas MEDP's P/E ratio is 22.58. In terms of profitability, DHR-PB's ROE is +0.07%, compared to MEDP's ROE of +0.54%. Regarding short-term risk, DHR-PB is less volatile compared to MEDP. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs SKHHY Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, SKHHY has a market cap of 7.70B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while SKHHY trades at $16.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas SKHHY's P/E ratio is 22.59. In terms of profitability, DHR-PB's ROE is +0.07%, compared to SKHHY's ROE of +0.07%. Regarding short-term risk, DHR-PB is less volatile compared to SKHHY. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs SKHCF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, SKHCF has a market cap of 7.11B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while SKHCF trades at $14.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas SKHCF's P/E ratio is 20.56. In terms of profitability, DHR-PB's ROE is +0.07%, compared to SKHCF's ROE of +0.05%. Regarding short-term risk, DHR-PB is less volatile compared to SKHCF. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs CRL Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, CRL has a market cap of 6.82B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while CRL trades at $138.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas CRL's P/E ratio is 660.90. In terms of profitability, DHR-PB's ROE is +0.07%, compared to CRL's ROE of +0.00%. Regarding short-term risk, DHR-PB is less volatile compared to CRL. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs DSRLF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, DSRLF has a market cap of 5.81B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while DSRLF trades at $107.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas DSRLF's P/E ratio is 28.35. In terms of profitability, DHR-PB's ROE is +0.07%, compared to DSRLF's ROE of +0.09%. Regarding short-term risk, DHR-PB is more volatile compared to DSRLF. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs GH Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, GH has a market cap of 5.17B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while GH trades at $41.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas GH's P/E ratio is -12.31. In terms of profitability, DHR-PB's ROE is +0.07%, compared to GH's ROE of +3.69%. Regarding short-term risk, DHR-PB is less volatile compared to GH. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs HNGZY Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, HNGZY has a market cap of 4.48B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while HNGZY trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas HNGZY's P/E ratio is 26.67. In terms of profitability, DHR-PB's ROE is +0.07%, compared to HNGZY's ROE of +0.02%. Regarding short-term risk, DHR-PB is less volatile compared to HNGZY. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs SYNH Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, SYNH has a market cap of 4.46B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas SYNH's P/E ratio is 61.40. In terms of profitability, DHR-PB's ROE is +0.07%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, DHR-PB is more volatile compared to SYNH. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs RDNT Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, RDNT has a market cap of 4.13B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while RDNT trades at $55.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas RDNT's P/E ratio is 1393.50. In terms of profitability, DHR-PB's ROE is +0.07%, compared to RDNT's ROE of +0.02%. Regarding short-term risk, DHR-PB is less volatile compared to RDNT. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs SHC Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, SHC has a market cap of 3.35B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while SHC trades at $11.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas SHC's P/E ratio is 73.88. In terms of profitability, DHR-PB's ROE is +0.07%, compared to SHC's ROE of +0.06%. Regarding short-term risk, DHR-PB is less volatile compared to SHC. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs OLK Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, OLK has a market cap of 3.24B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas OLK's P/E ratio is -96.59. In terms of profitability, DHR-PB's ROE is +0.07%, compared to OLK's ROE of -0.07%. Regarding short-term risk, DHR-PB is more volatile compared to OLK. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs TWST Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, TWST has a market cap of 1.85B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while TWST trades at $30.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas TWST's P/E ratio is -9.48. In terms of profitability, DHR-PB's ROE is +0.07%, compared to TWST's ROE of -0.41%. Regarding short-term risk, DHR-PB is less volatile compared to TWST. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs VIMGF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, VIMGF has a market cap of 1.81B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while VIMGF trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas VIMGF's P/E ratio is 70.00. In terms of profitability, DHR-PB's ROE is +0.07%, compared to VIMGF's ROE of +0.03%. Regarding short-term risk, DHR-PB is more volatile compared to VIMGF. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs VIVO Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, VIVO has a market cap of 1.49B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while VIVO trades at $33.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas VIVO's P/E ratio is 21.09. In terms of profitability, DHR-PB's ROE is +0.07%, compared to VIVO's ROE of +0.12%. Regarding short-term risk, DHR-PB is more volatile compared to VIVO. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs NEOG Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, NEOG has a market cap of 1.30B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while NEOG trades at $5.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas NEOG's P/E ratio is -2.68. In terms of profitability, DHR-PB's ROE is +0.07%, compared to NEOG's ROE of -0.17%. Regarding short-term risk, DHR-PB is less volatile compared to NEOG. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs GRAL Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, GRAL has a market cap of 1.24B. Regarding current trading prices, DHR-PB is priced at $1,261.26, while GRAL trades at $35.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas GRAL's P/E ratio is -0.55. In terms of profitability, DHR-PB's ROE is +0.07%, compared to GRAL's ROE of -0.70%. Regarding short-term risk, DHR-PB is less volatile compared to GRAL. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs OPK Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, OPK has a market cap of 983.39M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while OPK trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas OPK's P/E ratio is -20.67. In terms of profitability, DHR-PB's ROE is +0.07%, compared to OPK's ROE of -0.03%. Regarding short-term risk, DHR-PB is less volatile compared to OPK. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs MRCHF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, MRCHF has a market cap of 962.56M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while MRCHF trades at $16.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas MRCHF's P/E ratio is -99.65. In terms of profitability, DHR-PB's ROE is +0.07%, compared to MRCHF's ROE of -0.04%. Regarding short-term risk, DHR-PB is less volatile compared to MRCHF. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs CDNA Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, CDNA has a market cap of 855.25M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while CDNA trades at $15.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas CDNA's P/E ratio is 13.71. In terms of profitability, DHR-PB's ROE is +0.07%, compared to CDNA's ROE of +0.18%. Regarding short-term risk, DHR-PB is less volatile compared to CDNA. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs FLGT Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, FLGT has a market cap of 599.74M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while FLGT trades at $19.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas FLGT's P/E ratio is -14.81. In terms of profitability, DHR-PB's ROE is +0.07%, compared to FLGT's ROE of -0.04%. Regarding short-term risk, DHR-PB is less volatile compared to FLGT. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs GRALV Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, GRALV has a market cap of 579.39M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas GRALV's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.07%, compared to GRALV's ROE of N/A. Regarding short-term risk, DHR-PB is less volatile compared to GRALV. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs CSTL Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, CSTL has a market cap of 484.62M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while CSTL trades at $16.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas CSTL's P/E ratio is -88.34. In terms of profitability, DHR-PB's ROE is +0.07%, compared to CSTL's ROE of -0.01%. Regarding short-term risk, DHR-PB is less volatile compared to CSTL. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs PSNL Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, PSNL has a market cap of 445.16M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while PSNL trades at $5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas PSNL's P/E ratio is -3.68. In terms of profitability, DHR-PB's ROE is +0.07%, compared to PSNL's ROE of -0.54%. Regarding short-term risk, DHR-PB is less volatile compared to PSNL. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs LAB Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, LAB has a market cap of 406.41M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while LAB trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas LAB's P/E ratio is -2.06. In terms of profitability, DHR-PB's ROE is +0.07%, compared to LAB's ROE of -0.27%. Regarding short-term risk, DHR-PB is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs CO Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, CO has a market cap of 400.08M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas CO's P/E ratio is 5.06. In terms of profitability, DHR-PB's ROE is +0.07%, compared to CO's ROE of +0.18%. Regarding short-term risk, DHR-PB is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs MYGN Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, MYGN has a market cap of 358.55M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while MYGN trades at $3.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas MYGN's P/E ratio is -2.76. In terms of profitability, DHR-PB's ROE is +0.07%, compared to MYGN's ROE of -0.15%. Regarding short-term risk, DHR-PB is less volatile compared to MYGN. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs FLDM Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, FLDM has a market cap of 294.19M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas FLDM's P/E ratio is -4.74. In terms of profitability, DHR-PB's ROE is +0.07%, compared to FLDM's ROE of -0.27%. Regarding short-term risk, DHR-PB is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs STIM Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, STIM has a market cap of 291.58M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while STIM trades at $4.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas STIM's P/E ratio is -3.21. In terms of profitability, DHR-PB's ROE is +0.07%, compared to STIM's ROE of -2.04%. Regarding short-term risk, DHR-PB is less volatile compared to STIM. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs NEO Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, NEO has a market cap of 207.17M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while NEO trades at $8.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas NEO's P/E ratio is -13.20. In terms of profitability, DHR-PB's ROE is +0.07%, compared to NEO's ROE of -0.09%. Regarding short-term risk, DHR-PB is less volatile compared to NEO. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs IDGXF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, IDGXF has a market cap of 187.19M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while IDGXF trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas IDGXF's P/E ratio is 8.05. In terms of profitability, DHR-PB's ROE is +0.07%, compared to IDGXF's ROE of +0.24%. Regarding short-term risk, DHR-PB is less volatile compared to IDGXF. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs ATLN Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, ATLN has a market cap of 186.62M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while ATLN trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas ATLN's P/E ratio is -0.81. In terms of profitability, DHR-PB's ROE is +0.07%, compared to ATLN's ROE of -19.68%. Regarding short-term risk, DHR-PB is less volatile compared to ATLN. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs EDTXF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, EDTXF has a market cap of 177.44M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while EDTXF trades at $0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas EDTXF's P/E ratio is -15.56. In terms of profitability, DHR-PB's ROE is +0.07%, compared to EDTXF's ROE of +0.61%. Regarding short-term risk, DHR-PB is more volatile compared to EDTXF. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs AMCY Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, AMCY has a market cap of 171.27M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while AMCY trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas AMCY's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.07%, compared to AMCY's ROE of N/A. Regarding short-term risk, DHR-PB is more volatile compared to AMCY. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs NNGRF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, NNGRF has a market cap of 164.30M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while NNGRF trades at $12.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas NNGRF's P/E ratio is 60.75. In terms of profitability, DHR-PB's ROE is +0.07%, compared to NNGRF's ROE of -0.07%. Regarding short-term risk, DHR-PB is more volatile compared to NNGRF. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs CORBF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, CORBF has a market cap of 145.97M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while CORBF trades at $1.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas CORBF's P/E ratio is 3.03. In terms of profitability, DHR-PB's ROE is +0.07%, compared to CORBF's ROE of +0.11%. Regarding short-term risk, DHR-PB is less volatile compared to CORBF. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs ACRS Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, ACRS has a market cap of 136.43M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while ACRS trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas ACRS's P/E ratio is -0.74. In terms of profitability, DHR-PB's ROE is +0.07%, compared to ACRS's ROE of -0.94%. Regarding short-term risk, DHR-PB is less volatile compared to ACRS. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs THOXF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, THOXF has a market cap of 130.94M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while THOXF trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas THOXF's P/E ratio is -14.40. In terms of profitability, DHR-PB's ROE is +0.07%, compared to THOXF's ROE of -0.91%. Regarding short-term risk, DHR-PB is less volatile compared to THOXF. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs GTH Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, GTH has a market cap of 127.29M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas GTH's P/E ratio is -1.11. In terms of profitability, DHR-PB's ROE is +0.07%, compared to GTH's ROE of +0.00%. Regarding short-term risk, DHR-PB is less volatile compared to GTH. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs DIUXF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, DIUXF has a market cap of 115.49M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while DIUXF trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas DIUXF's P/E ratio is 136.72. In terms of profitability, DHR-PB's ROE is +0.07%, compared to DIUXF's ROE of -0.07%. Regarding short-term risk, DHR-PB is more volatile compared to DIUXF. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs GENE Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, GENE has a market cap of 111.24M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas GENE's P/E ratio is -38.25. In terms of profitability, DHR-PB's ROE is +0.07%, compared to GENE's ROE of -3.62%. Regarding short-term risk, DHR-PB is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs XGN Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, XGN has a market cap of 102.79M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while XGN trades at $5.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas XGN's P/E ratio is -6.80. In terms of profitability, DHR-PB's ROE is +0.07%, compared to XGN's ROE of -1.34%. Regarding short-term risk, DHR-PB is less volatile compared to XGN. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs ANPCF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, ANPCF has a market cap of 99.98M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while ANPCF trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas ANPCF's P/E ratio is -3.10. In terms of profitability, DHR-PB's ROE is +0.07%, compared to ANPCF's ROE of -0.54%. Regarding short-term risk, DHR-PB is less volatile compared to ANPCF. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs MDXH Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, MDXH has a market cap of 92.56M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while MDXH trades at $1.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas MDXH's P/E ratio is -1.61. In terms of profitability, DHR-PB's ROE is +0.07%, compared to MDXH's ROE of -6.91%. Regarding short-term risk, DHR-PB is less volatile compared to MDXH. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs SERA Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, SERA has a market cap of 81.48M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while SERA trades at $2.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas SERA's P/E ratio is -2.24. In terms of profitability, DHR-PB's ROE is +0.07%, compared to SERA's ROE of -0.58%. Regarding short-term risk, DHR-PB is less volatile compared to SERA. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs TIHE Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, TIHE has a market cap of 71.85M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while TIHE trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas TIHE's P/E ratio is 0.32. In terms of profitability, DHR-PB's ROE is +0.07%, compared to TIHE's ROE of +0.01%. Regarding short-term risk, DHR-PB is more volatile compared to TIHE. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs PRE Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, PRE has a market cap of 70.22M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while PRE trades at $5.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas PRE's P/E ratio is -1.45. In terms of profitability, DHR-PB's ROE is +0.07%, compared to PRE's ROE of -0.25%. Regarding short-term risk, DHR-PB is less volatile compared to PRE. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs PRENW Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, PRENW has a market cap of 67.78M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas PRENW's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.07%, compared to PRENW's ROE of -0.25%. Regarding short-term risk, DHR-PB is more volatile compared to PRENW. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs NOTV Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, NOTV has a market cap of 66.38M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while NOTV trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas NOTV's P/E ratio is -0.43. In terms of profitability, DHR-PB's ROE is +0.07%, compared to NOTV's ROE of -0.66%. Regarding short-term risk, DHR-PB is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs BIOGF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, BIOGF has a market cap of 65.41M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while BIOGF trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas BIOGF's P/E ratio is -0.67. In terms of profitability, DHR-PB's ROE is +0.07%, compared to BIOGF's ROE of +2.04%. Regarding short-term risk, DHR-PB is more volatile compared to BIOGF. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs PCNEF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, PCNEF has a market cap of 63.00M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while PCNEF trades at $2.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas PCNEF's P/E ratio is -8.44. In terms of profitability, DHR-PB's ROE is +0.07%, compared to PCNEF's ROE of -0.21%. Regarding short-term risk, DHR-PB is more volatile compared to PCNEF. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs BDSX Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, BDSX has a market cap of 54.42M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while BDSX trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas BDSX's P/E ratio is -1.13. In terms of profitability, DHR-PB's ROE is +0.07%, compared to BDSX's ROE of -2.16%. Regarding short-term risk, DHR-PB is less volatile compared to BDSX. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs PFGTF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, PFGTF has a market cap of 50.58M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while PFGTF trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas PFGTF's P/E ratio is -3.11. In terms of profitability, DHR-PB's ROE is +0.07%, compared to PFGTF's ROE of -0.41%. Regarding short-term risk, DHR-PB is less volatile compared to PFGTF. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs VNRX Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, VNRX has a market cap of 50.19M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while VNRX trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas VNRX's P/E ratio is -1.61. In terms of profitability, DHR-PB's ROE is +0.07%, compared to VNRX's ROE of +1.29%. Regarding short-term risk, DHR-PB is less volatile compared to VNRX. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs OPGN Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, OPGN has a market cap of 49.43M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while OPGN trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas OPGN's P/E ratio is -0.32. In terms of profitability, DHR-PB's ROE is +0.07%, compared to OPGN's ROE of +1.20%. Regarding short-term risk, DHR-PB is less volatile compared to OPGN. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs BIOQ Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, BIOQ has a market cap of 44.69M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while BIOQ trades at $50.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas BIOQ's P/E ratio is 14.41. In terms of profitability, DHR-PB's ROE is +0.07%, compared to BIOQ's ROE of -0.06%. Regarding short-term risk, DHR-PB is less volatile compared to BIOQ. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs DRIO Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, DRIO has a market cap of 31.17M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while DRIO trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas DRIO's P/E ratio is -1.23. In terms of profitability, DHR-PB's ROE is +0.07%, compared to DRIO's ROE of -0.47%. Regarding short-term risk, DHR-PB is less volatile compared to DRIO. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs STRRP Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, STRRP has a market cap of 29.70M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while STRRP trades at $9.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas STRRP's P/E ratio is -4.64. In terms of profitability, DHR-PB's ROE is +0.07%, compared to STRRP's ROE of -0.18%. Regarding short-term risk, DHR-PB is more volatile compared to STRRP. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs CLIFF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, CLIFF has a market cap of 29.65M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while CLIFF trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas CLIFF's P/E ratio is -1.93. In terms of profitability, DHR-PB's ROE is +0.07%, compared to CLIFF's ROE of -0.08%. Regarding short-term risk, DHR-PB is less volatile compared to CLIFF. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs ANPCY Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, ANPCY has a market cap of 27.08M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while ANPCY trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas ANPCY's P/E ratio is -0.92. In terms of profitability, DHR-PB's ROE is +0.07%, compared to ANPCY's ROE of -0.75%. Regarding short-term risk, DHR-PB is more volatile compared to ANPCY. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs AKU Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, AKU has a market cap of 26.27M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas AKU's P/E ratio is -0.13. In terms of profitability, DHR-PB's ROE is +0.07%, compared to AKU's ROE of -5.32%. Regarding short-term risk, DHR-PB is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs SNANF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, SNANF has a market cap of 23.89M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while SNANF trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas SNANF's P/E ratio is -11.02. In terms of profitability, DHR-PB's ROE is +0.07%, compared to SNANF's ROE of -2.51%. Regarding short-term risk, DHR-PB is more volatile compared to SNANF. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs PMSNF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, PMSNF has a market cap of 23.61M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while PMSNF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas PMSNF's P/E ratio is -4.00. In terms of profitability, DHR-PB's ROE is +0.07%, compared to PMSNF's ROE of +0.69%. Regarding short-term risk, DHR-PB is less volatile compared to PMSNF. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs VILGF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, VILGF has a market cap of 20.67M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while VILGF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas VILGF's P/E ratio is -0.30. In terms of profitability, DHR-PB's ROE is +0.07%, compared to VILGF's ROE of N/A. Regarding short-term risk, DHR-PB is more volatile compared to VILGF. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs ADVB Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, ADVB has a market cap of 20.61M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while ADVB trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas ADVB's P/E ratio is -6.80. In terms of profitability, DHR-PB's ROE is +0.07%, compared to ADVB's ROE of -2.41%. Regarding short-term risk, DHR-PB is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs IMMVF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, IMMVF has a market cap of 19.33M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while IMMVF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas IMMVF's P/E ratio is -0.32. In terms of profitability, DHR-PB's ROE is +0.07%, compared to IMMVF's ROE of -2.69%. Regarding short-term risk, DHR-PB is less volatile compared to IMMVF. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs LDXHF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, LDXHF has a market cap of 19.09M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while LDXHF trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas LDXHF's P/E ratio is -2.55. In terms of profitability, DHR-PB's ROE is +0.07%, compared to LDXHF's ROE of -1.38%. Regarding short-term risk, DHR-PB is less volatile compared to LDXHF. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs PCHM Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, PCHM has a market cap of 17.38M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while PCHM trades at $2.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas PCHM's P/E ratio is -0.02. In terms of profitability, DHR-PB's ROE is +0.07%, compared to PCHM's ROE of +0.53%. Regarding short-term risk, DHR-PB is more volatile compared to PCHM. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs CEMI Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, CEMI has a market cap of 16.71M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas CEMI's P/E ratio is -0.63. In terms of profitability, DHR-PB's ROE is +0.07%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, DHR-PB is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs ENZ Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, ENZ has a market cap of 16.44M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas ENZ's P/E ratio is -2.24. In terms of profitability, DHR-PB's ROE is +0.07%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, DHR-PB is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs PMD Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, PMD has a market cap of 15.74M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas PMD's P/E ratio is -5.24. In terms of profitability, DHR-PB's ROE is +0.07%, compared to PMD's ROE of -0.33%. Regarding short-term risk, DHR-PB is less volatile compared to PMD. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs BMKDF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, BMKDF has a market cap of 15.45M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while BMKDF trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas BMKDF's P/E ratio is -17.00. In terms of profitability, DHR-PB's ROE is +0.07%, compared to BMKDF's ROE of +2.24%. Regarding short-term risk, DHR-PB is less volatile compared to BMKDF. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs ABDXF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, ABDXF has a market cap of 13.55M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while ABDXF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas ABDXF's P/E ratio is -1.40. In terms of profitability, DHR-PB's ROE is +0.07%, compared to ABDXF's ROE of -0.63%. Regarding short-term risk, DHR-PB is more volatile compared to ABDXF. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs ME Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, ME has a market cap of 13.34M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas ME's P/E ratio is -0.03. In terms of profitability, DHR-PB's ROE is +0.07%, compared to ME's ROE of -3.04%. Regarding short-term risk, DHR-PB is less volatile compared to ME. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs BNGO Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, BNGO has a market cap of 11.90M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while BNGO trades at $3.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas BNGO's P/E ratio is -0.04. In terms of profitability, DHR-PB's ROE is +0.07%, compared to BNGO's ROE of -1.81%. Regarding short-term risk, DHR-PB is less volatile compared to BNGO. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs IZOZF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, IZOZF has a market cap of 11.50M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while IZOZF trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas IZOZF's P/E ratio is -6.33. In terms of profitability, DHR-PB's ROE is +0.07%, compared to IZOZF's ROE of +0.47%. Regarding short-term risk, DHR-PB is more volatile compared to IZOZF. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs PRPO Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, PRPO has a market cap of 10.02M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while PRPO trades at $6.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas PRPO's P/E ratio is -2.26. In terms of profitability, DHR-PB's ROE is +0.07%, compared to PRPO's ROE of -0.35%. Regarding short-term risk, DHR-PB is more volatile compared to PRPO. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs CNTG Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, CNTG has a market cap of 9.43M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas CNTG's P/E ratio is -0.23. In terms of profitability, DHR-PB's ROE is +0.07%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, DHR-PB is less volatile compared to CNTG. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs MXDHF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, MXDHF has a market cap of 8.65M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while MXDHF trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas MXDHF's P/E ratio is -0.12. In terms of profitability, DHR-PB's ROE is +0.07%, compared to MXDHF's ROE of -6.91%. Regarding short-term risk, DHR-PB is more volatile compared to MXDHF. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs INBS Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, INBS has a market cap of 8.24M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while INBS trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas INBS's P/E ratio is 10.08. In terms of profitability, DHR-PB's ROE is +0.07%, compared to INBS's ROE of -1.43%. Regarding short-term risk, DHR-PB is less volatile compared to INBS. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs STRR Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, STRR has a market cap of 7.98M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while STRR trades at $2.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas STRR's P/E ratio is -0.75. In terms of profitability, DHR-PB's ROE is +0.07%, compared to STRR's ROE of -0.18%. Regarding short-term risk, DHR-PB is less volatile compared to STRR. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs MYNZ Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, MYNZ has a market cap of 7.45M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while MYNZ trades at $2.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas MYNZ's P/E ratio is -0.11. In terms of profitability, DHR-PB's ROE is +0.07%, compared to MYNZ's ROE of -16.99%. Regarding short-term risk, DHR-PB is less volatile compared to MYNZ. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs VRCDF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, VRCDF has a market cap of 7.28M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while VRCDF trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas VRCDF's P/E ratio is -1.00. In terms of profitability, DHR-PB's ROE is +0.07%, compared to VRCDF's ROE of -0.73%. Regarding short-term risk, DHR-PB is less volatile compared to VRCDF. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs TDSGF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, TDSGF has a market cap of 7.13M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while TDSGF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas TDSGF's P/E ratio is -2.38. In terms of profitability, DHR-PB's ROE is +0.07%, compared to TDSGF's ROE of -3.19%. Regarding short-term risk, DHR-PB is more volatile compared to TDSGF. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs GNTLF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, GNTLF has a market cap of 6.07M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while GNTLF trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas GNTLF's P/E ratio is -16.67. In terms of profitability, DHR-PB's ROE is +0.07%, compared to GNTLF's ROE of -3.62%. Regarding short-term risk, DHR-PB is more volatile compared to GNTLF. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs SQIDF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, SQIDF has a market cap of 6.07M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while SQIDF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas SQIDF's P/E ratio is -0.37. In terms of profitability, DHR-PB's ROE is +0.07%, compared to SQIDF's ROE of +0.00%. Regarding short-term risk, DHR-PB is less volatile compared to SQIDF. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs NVTA Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, NVTA has a market cap of 5.44M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas NVTA's P/E ratio is -0.00. In terms of profitability, DHR-PB's ROE is +0.07%, compared to NVTA's ROE of +1.79%. Regarding short-term risk, DHR-PB is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs APDN Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, APDN has a market cap of 5.33M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while APDN trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas APDN's P/E ratio is -0.03. In terms of profitability, DHR-PB's ROE is +0.07%, compared to APDN's ROE of -1.00%. Regarding short-term risk, DHR-PB is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs LMDXW Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, LMDXW has a market cap of 5.10M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, DHR-PB's ROE is +0.07%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, DHR-PB is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs LMDX Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, LMDX has a market cap of 5.10M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas LMDX's P/E ratio is -0.01. In terms of profitability, DHR-PB's ROE is +0.07%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, DHR-PB is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs BGLC Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, BGLC has a market cap of 4.80M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while BGLC trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas BGLC's P/E ratio is -2.97. In terms of profitability, DHR-PB's ROE is +0.07%, compared to BGLC's ROE of -0.17%. Regarding short-term risk, DHR-PB is less volatile compared to BGLC. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs SLDX Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, SLDX has a market cap of 4.78M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while SLDX trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas SLDX's P/E ratio is -0.01. In terms of profitability, DHR-PB's ROE is +0.07%, compared to SLDX's ROE of +0.06%. Regarding short-term risk, DHR-PB is less volatile compared to SLDX. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs CHEK Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, CHEK has a market cap of 4.75M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while CHEK trades at $0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas CHEK's P/E ratio is -0.38. In terms of profitability, DHR-PB's ROE is +0.07%, compared to CHEK's ROE of -0.52%. Regarding short-term risk, DHR-PB is less volatile compared to CHEK. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs RNVA Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, RNVA has a market cap of 4.31M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while RNVA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas RNVA's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.07%, compared to RNVA's ROE of +0.23%. Regarding short-term risk, DHR-PB is more volatile compared to RNVA. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs JMPHF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, JMPHF has a market cap of 4.18M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while JMPHF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas JMPHF's P/E ratio is -0.91. In terms of profitability, DHR-PB's ROE is +0.07%, compared to JMPHF's ROE of -0.11%. Regarding short-term risk, DHR-PB is less volatile compared to JMPHF. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs TTOO Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, TTOO has a market cap of 4.14M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while TTOO trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas TTOO's P/E ratio is -4.92. In terms of profitability, DHR-PB's ROE is +0.07%, compared to TTOO's ROE of +2.06%. Regarding short-term risk, DHR-PB is less volatile compared to TTOO. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs BIAF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, BIAF has a market cap of 3.76M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while BIAF trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas BIAF's P/E ratio is -0.27. In terms of profitability, DHR-PB's ROE is +0.07%, compared to BIAF's ROE of -2.51%. Regarding short-term risk, DHR-PB is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs BIAFW Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, BIAFW has a market cap of 3.65M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while BIAFW trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas BIAFW's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.07%, compared to BIAFW's ROE of -2.51%. Regarding short-term risk, DHR-PB is more volatile compared to BIAFW. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs SZLSF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, SZLSF has a market cap of 3.57M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while SZLSF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas SZLSF's P/E ratio is -0.02. In terms of profitability, DHR-PB's ROE is +0.07%, compared to SZLSF's ROE of +0.13%. Regarding short-term risk, DHR-PB is less volatile compared to SZLSF. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs IDXG Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, IDXG has a market cap of 3.36M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while IDXG trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas IDXG's P/E ratio is 1.85. In terms of profitability, DHR-PB's ROE is +0.07%, compared to IDXG's ROE of -0.66%. Regarding short-term risk, DHR-PB is less volatile compared to IDXG. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs DMTK Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, DMTK has a market cap of 3.29M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas DMTK's P/E ratio is -0.04. In terms of profitability, DHR-PB's ROE is +0.07%, compared to DMTK's ROE of -1.39%. Regarding short-term risk, DHR-PB is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs AWH Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, AWH has a market cap of 2.89M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas AWH's P/E ratio is -0.09. In terms of profitability, DHR-PB's ROE is +0.07%, compared to AWH's ROE of +5.16%. Regarding short-term risk, DHR-PB is less volatile compared to AWH. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs ISPC Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, ISPC has a market cap of 2.86M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while ISPC trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas ISPC's P/E ratio is -0.07. In terms of profitability, DHR-PB's ROE is +0.07%, compared to ISPC's ROE of -2.39%. Regarding short-term risk, DHR-PB is less volatile compared to ISPC. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs IDTA Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, IDTA has a market cap of 2.83M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while IDTA trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas IDTA's P/E ratio is 6.99. In terms of profitability, DHR-PB's ROE is +0.07%, compared to IDTA's ROE of +0.36%. Regarding short-term risk, DHR-PB is more volatile compared to IDTA. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs AVCRF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, AVCRF has a market cap of 2.83M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while AVCRF trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas AVCRF's P/E ratio is -2.79. In terms of profitability, DHR-PB's ROE is +0.07%, compared to AVCRF's ROE of +0.05%. Regarding short-term risk, DHR-PB is less volatile compared to AVCRF. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs SQL Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, SQL has a market cap of 2.51M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas SQL's P/E ratio is -0.40. In terms of profitability, DHR-PB's ROE is +0.07%, compared to SQL's ROE of -0.67%. Regarding short-term risk, DHR-PB is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs BNR Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, BNR has a market cap of 2.50M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while BNR trades at $2.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas BNR's P/E ratio is -0.50. In terms of profitability, DHR-PB's ROE is +0.07%, compared to BNR's ROE of -0.53%. Regarding short-term risk, DHR-PB is less volatile compared to BNR. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs NDRA Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, NDRA has a market cap of 1.83M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while NDRA trades at $3.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas NDRA's P/E ratio is -0.06. In terms of profitability, DHR-PB's ROE is +0.07%, compared to NDRA's ROE of -2.11%. Regarding short-term risk, DHR-PB is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs ICBU Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, ICBU has a market cap of 1.64M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while ICBU trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas ICBU's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.07%, compared to ICBU's ROE of +0.70%. Regarding short-term risk, DHR-PB is less volatile compared to ICBU. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs IBXXF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, IBXXF has a market cap of 1.61M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while IBXXF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas IBXXF's P/E ratio is -0.27. In terms of profitability, DHR-PB's ROE is +0.07%, compared to IBXXF's ROE of +0.55%. Regarding short-term risk, DHR-PB is less volatile compared to IBXXF. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs IVRO Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, IVRO has a market cap of 1.53M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while IVRO trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas IVRO's P/E ratio is -0.84. In terms of profitability, DHR-PB's ROE is +0.07%, compared to IVRO's ROE of +0.08%. Regarding short-term risk, DHR-PB is less volatile compared to IVRO. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs DIGP Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, DIGP has a market cap of 1.09M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while DIGP trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas DIGP's P/E ratio is -1.04. In terms of profitability, DHR-PB's ROE is +0.07%, compared to DIGP's ROE of +0.05%. Regarding short-term risk, DHR-PB is less volatile compared to DIGP. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs HTGM Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, HTGM has a market cap of 1.06M. Regarding current trading prices, DHR-PB is priced at $1,261.26, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas HTGM's P/E ratio is -0.03. In terms of profitability, DHR-PB's ROE is +0.07%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, DHR-PB is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs SCRSF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, SCRSF has a market cap of 855366.00. Regarding current trading prices, DHR-PB is priced at $1,261.26, while SCRSF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas SCRSF's P/E ratio is -0.09. In terms of profitability, DHR-PB's ROE is +0.07%, compared to SCRSF's ROE of +2.91%. Regarding short-term risk, DHR-PB is more volatile compared to SCRSF. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs SQLLW Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, SQLLW has a market cap of 837087.00. Regarding current trading prices, DHR-PB is priced at $1,261.26, while SQLLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas SQLLW's P/E ratio is -0.04. In terms of profitability, DHR-PB's ROE is +0.07%, compared to SQLLW's ROE of -19.68%. Regarding short-term risk, DHR-PB is less volatile compared to SQLLW. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs RSHN Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, RSHN has a market cap of 817464.00. Regarding current trading prices, DHR-PB is priced at $1,261.26, while RSHN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas RSHN's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.07%, compared to RSHN's ROE of -5.42%. Regarding short-term risk, DHR-PB is less volatile compared to RSHN. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs EPGNF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, EPGNF has a market cap of 692790.00. Regarding current trading prices, DHR-PB is priced at $1,261.26, while EPGNF trades at $0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas EPGNF's P/E ratio is -0.04. In terms of profitability, DHR-PB's ROE is +0.07%, compared to EPGNF's ROE of -4.14%. Regarding short-term risk, DHR-PB is less volatile compared to EPGNF. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs NSTM Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, NSTM has a market cap of 468815.00. Regarding current trading prices, DHR-PB is priced at $1,261.26, while NSTM trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas NSTM's P/E ratio is -0.14. In terms of profitability, DHR-PB's ROE is +0.07%, compared to NSTM's ROE of +0.87%. Regarding short-term risk, DHR-PB is less volatile compared to NSTM. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs BIOC Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, BIOC has a market cap of 450786.00. Regarding current trading prices, DHR-PB is priced at $1,261.26, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas BIOC's P/E ratio is -0.01. In terms of profitability, DHR-PB's ROE is +0.07%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, DHR-PB is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs TRIB Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, TRIB has a market cap of 428554.00. Regarding current trading prices, DHR-PB is priced at $1,261.26, while TRIB trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas TRIB's P/E ratio is -0.34. In terms of profitability, DHR-PB's ROE is +0.07%, compared to TRIB's ROE of +0.79%. Regarding short-term risk, DHR-PB is less volatile compared to TRIB. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs MBGNF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, MBGNF has a market cap of 172578.00. Regarding current trading prices, DHR-PB is priced at $1,261.26, while MBGNF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas MBGNF's P/E ratio is -1.00. In terms of profitability, DHR-PB's ROE is +0.07%, compared to MBGNF's ROE of +0.37%. Regarding short-term risk, DHR-PB is more volatile compared to MBGNF. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs NVTAQ Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, NVTAQ has a market cap of 85948.00. Regarding current trading prices, DHR-PB is priced at $1,261.26, while NVTAQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas NVTAQ's P/E ratio is -0.00. In terms of profitability, DHR-PB's ROE is +0.07%, compared to NVTAQ's ROE of +1.79%. Regarding short-term risk, DHR-PB is less volatile compared to NVTAQ. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs ARYC Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, ARYC has a market cap of 79348.00. Regarding current trading prices, DHR-PB is priced at $1,261.26, while ARYC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas ARYC's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.07%, compared to ARYC's ROE of +0.55%. Regarding short-term risk, DHR-PB is less volatile compared to ARYC. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs HCLC Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, HCLC has a market cap of 73985.00. Regarding current trading prices, DHR-PB is priced at $1,261.26, while HCLC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas HCLC's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.07%, compared to HCLC's ROE of +0.11%. Regarding short-term risk, DHR-PB is more volatile compared to HCLC. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs MEDVF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, MEDVF has a market cap of 54038.00. Regarding current trading prices, DHR-PB is priced at $1,261.26, while MEDVF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas MEDVF's P/E ratio is -0.03. In terms of profitability, DHR-PB's ROE is +0.07%, compared to MEDVF's ROE of +0.57%. Regarding short-term risk, DHR-PB is more volatile compared to MEDVF. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs CHHL Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, CHHL has a market cap of 37320.00. Regarding current trading prices, DHR-PB is priced at $1,261.26, while CHHL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas CHHL's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.07%, compared to CHHL's ROE of N/A. Regarding short-term risk, DHR-PB is less volatile compared to CHHL. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs IHTI Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, IHTI has a market cap of 32514.00. Regarding current trading prices, DHR-PB is priced at $1,261.26, while IHTI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas IHTI's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.07%, compared to IHTI's ROE of +0.00%. Regarding short-term risk, DHR-PB is less volatile compared to IHTI. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs MEDD Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, MEDD has a market cap of 31910.00. Regarding current trading prices, DHR-PB is priced at $1,261.26, while MEDD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas MEDD's P/E ratio is -0.01. In terms of profitability, DHR-PB's ROE is +0.07%, compared to MEDD's ROE of +0.74%. Regarding short-term risk, DHR-PB is more volatile compared to MEDD. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs CGNH Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, CGNH has a market cap of 24046.00. Regarding current trading prices, DHR-PB is priced at $1,261.26, while CGNH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas CGNH's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.07%, compared to CGNH's ROE of +1.41%. Regarding short-term risk, DHR-PB is less volatile compared to CGNH. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs TOMDF Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, TOMDF has a market cap of 14081.00. Regarding current trading prices, DHR-PB is priced at $1,261.26, while TOMDF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas TOMDF's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.07%, compared to TOMDF's ROE of +0.84%. Regarding short-term risk, DHR-PB is less volatile compared to TOMDF. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs ABMC Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, ABMC has a market cap of 4810.00. Regarding current trading prices, DHR-PB is priced at $1,261.26, while ABMC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas ABMC's P/E ratio is 0.01. In terms of profitability, DHR-PB's ROE is +0.07%, compared to ABMC's ROE of +0.86%. Regarding short-term risk, DHR-PB is more volatile compared to ABMC. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs RGDXQ Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, RGDXQ has a market cap of 3880.00. Regarding current trading prices, DHR-PB is priced at $1,261.26, while RGDXQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas RGDXQ's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.07%, compared to RGDXQ's ROE of -1.27%. Regarding short-term risk, DHR-PB is less volatile compared to RGDXQ. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs DMTKQ Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, DMTKQ has a market cap of 3525.00. Regarding current trading prices, DHR-PB is priced at $1,261.26, while DMTKQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas DMTKQ's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.07%, compared to DMTKQ's ROE of -0.80%. Regarding short-term risk, DHR-PB is less volatile compared to DMTKQ. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs GWHP Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, GWHP has a market cap of 1313.00. Regarding current trading prices, DHR-PB is priced at $1,261.26, while GWHP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas GWHP's P/E ratio is -0.00. In terms of profitability, DHR-PB's ROE is +0.07%, compared to GWHP's ROE of +0.00%. Regarding short-term risk, DHR-PB is less volatile compared to GWHP. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs CYPS Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, CYPS has a market cap of 811.00. Regarding current trading prices, DHR-PB is priced at $1,261.26, while CYPS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas CYPS's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.07%, compared to CYPS's ROE of N/A. Regarding short-term risk, DHR-PB is less volatile compared to CYPS. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs ROSGQ Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, ROSGQ has a market cap of 593.00. Regarding current trading prices, DHR-PB is priced at $1,261.26, while ROSGQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas ROSGQ's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.07%, compared to ROSGQ's ROE of N/A. Regarding short-term risk, DHR-PB is more volatile compared to ROSGQ. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs BIOCQ Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, BIOCQ has a market cap of 263.00. Regarding current trading prices, DHR-PB is priced at $1,261.26, while BIOCQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas BIOCQ's P/E ratio is -0.00. In terms of profitability, DHR-PB's ROE is +0.07%, compared to BIOCQ's ROE of -1.38%. Regarding short-term risk, DHR-PB is more volatile compared to BIOCQ. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs HTGMQ Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, HTGMQ has a market cap of 221.00. Regarding current trading prices, DHR-PB is priced at $1,261.26, while HTGMQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas HTGMQ's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.07%, compared to HTGMQ's ROE of -2.73%. Regarding short-term risk, DHR-PB is more volatile compared to HTGMQ. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs OPGX Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, OPGX has a market cap of 17.00. Regarding current trading prices, DHR-PB is priced at $1,261.26, while OPGX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas OPGX's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.07%, compared to OPGX's ROE of +0.46%. Regarding short-term risk, DHR-PB is more volatile compared to OPGX. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs AGHC Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, AGHC comparison data is unavailable. Regarding current trading prices, DHR-PB is priced at $1,261.26, while AGHC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas AGHC's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.07%, compared to AGHC's ROE of +2.90%. Regarding short-term risk, DHR-PB is more volatile compared to AGHC. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs EPGNY Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, EPGNY comparison data is unavailable. Regarding current trading prices, DHR-PB is priced at $1,261.26, while EPGNY trades at $2.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas EPGNY's P/E ratio is -1.60. In terms of profitability, DHR-PB's ROE is +0.07%, compared to EPGNY's ROE of -0.19%. Regarding short-term risk, DHR-PB is more volatile compared to EPGNY. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs OCDX Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, OCDX comparison data is unavailable. Regarding current trading prices, DHR-PB is priced at $1,261.26, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas OCDX's P/E ratio is -42.28. In terms of profitability, DHR-PB's ROE is +0.07%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, DHR-PB is less volatile compared to OCDX. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs DHR-PA Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, DHR-PA comparison data is unavailable. Regarding current trading prices, DHR-PB is priced at $1,261.26, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, DHR-PB's ROE is +0.07%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, DHR-PB is less volatile compared to DHR-PA. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs BGNX Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, BGNX comparison data is unavailable. Regarding current trading prices, DHR-PB is priced at $1,261.26, while BGNX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas BGNX's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.07%, compared to BGNX's ROE of N/A. Regarding short-term risk, DHR-PB is more volatile compared to BGNX. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs MRPS Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, MRPS comparison data is unavailable. Regarding current trading prices, DHR-PB is priced at $1,261.26, while MRPS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas MRPS's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.07%, compared to MRPS's ROE of N/A. Regarding short-term risk, DHR-PB is more volatile compared to MRPS. This indicates potentially higher risk in terms of short-term price fluctuations for DHR-PB.
DHR-PB vs MEUSW Comparison
DHR-PB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.76B. In comparison, MEUSW comparison data is unavailable. Regarding current trading prices, DHR-PB is priced at $1,261.26, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas MEUSW's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.07%, compared to MEUSW's ROE of -3.04%. Regarding short-term risk, DHR-PB is less volatile compared to MEUSW. This indicates potentially lower risk in terms of short-term price fluctuations for DHR-PB.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DHR-PB | $1,261.26 | -0.78% | 916.76B | 146.01 | $8.64 | +0.59% |
| TMO | $403.04 | -1.88% | 152.15B | 23.64 | $17.05 | +0.40% |
| DHR | $189.58 | -2.69% | 135.68B | 36.74 | $5.16 | +0.59% |
| LZAGY | $70.35 | +1.75% | 50.75B | 65.14 | $1.08 | +0.75% |
| LZAGF | $699.91 | -2.77% | 49.22B | 64.57 | $10.84 | +0.63% |
| IDXX | $491.70 | +0.35% | 39.54B | 45.53 | $10.80 | N/A |
| A | $106.96 | -1.60% | 30.49B | 24.48 | $4.37 | +0.90% |
| IQV | $148.92 | -2.85% | 25.76B | 20.32 | $7.33 | N/A |
| WUXAY | $7.63 | -2.23% | 23.44B | 14.39 | $0.53 | +3.66% |
| MTD | $1,080.70 | -1.90% | 22.46B | 27.00 | $40.02 | N/A |